drugset / Trial / NCT01585038

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

NCT01585038

Phase 4 Completed 40 enrolled Indiana University Janssen Services, LLC · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the cardiovascular profiles of efavirenz and rilpivirine, which are two drugs used to treat HIV infection.

Timeline

Start
2012-07
Primary completion
2014-05
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 600 mg Oral
Comparator Rilpivirine Small molecule 25 mg Oral